MacuLogix, Inc. equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. The AdaptDx dark adaptometer enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/11/13 | $3,600,000 | Series A |
Ben Franklin Technology Partners of Central and Northern Pennsylvania Berwind Private Equity Life Sciences Greenhouse Roche Venture Fund | undisclosed |
| 03/04/19 | $38,700,000 | Series D |
Berwind Private Equity Fisk Ventures Life Sciences Greenhouse Roche Venture Fund Vivo Capital  | undisclosed |
